SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets EIR for transdermal manufacturing facility

01 Oct 2024 Evaluate

Zydus Lifesciences has received the EIR report from the United States Food and Drug Administration (USFDA) for the inspection conducted at its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. This facility underwent an inspection from July 15 to 19, 2024 and has been classified as Voluntary Action Indicated (VAI).

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×